Samsung Biologics today held its 15th Annual General Meeting (AGM), where shareholders approved all agenda items proposed by the board of directors, including the FY2025 consolidated financial statements and the appointment of executive directors as well as an independent director to the audit committee.
“We thank our shareholders for their continued support and confidence in the company,” said John Rim, President and CEO of Samsung Biologics. “We remain firmly committed to delivering shareholder value while driving sustainable growth. Building on our operational excellence and expanding global network, Samsung Biologics will continue to enhance its capabilities to support clients and contribute to the advancement of the biopharmaceutical industry.”
Samsung Biologics expects to maintain its growth momentum with a strong focus on quality and operational excellence, while continuing to invest across capacity, portfolio, and geographical expansion.
The company is further diversifying its global manufacturing footprint and service capabilities. Samsung Biologics has secured land for Bio Campus III, reinforcing its commitment to building infrastructure to support next-generation modalities and future biopharmaceutical demand. The company is also expanding its global presence through the planned acquisition of a manufacturing facility in Rockville, Maryland, U.S., strengthening regional proximity to clients and enhancing its global manufacturing network.
In addition, the company continues to pursue strategic collaborations and innovation initiatives. Recently, the company announced collaboration with the Coalition for Epidemic Preparedness Innovations (CEPI) to support outbreak-ready vaccine manufacturing, as well as partnership with Eli Lilly and Company to establish a new Lilly Gateway Labs site aimed at fostering the growth of emerging biotechnology companies.
Detailed information on the Annual General Meeting is available here.
Samsung Biologics today held its 15th Annual General Meeting (AGM), where shareholders approved all agenda items proposed by the board of directors, including the FY2025 consolidated financial statements and the appointment of executive directors as well as an independent director to the audit committee.
“We thank our shareholders for their continued support and confidence in the company,” said John Rim, President and CEO of Samsung Biologics. “We remain firmly committed to delivering shareholder value while driving sustainable growth. Building on our operational excellence and expanding global network, Samsung Biologics will continue to enhance its capabilities to support clients and contribute to the advancement of the biopharmaceutical industry.”
Samsung Biologics expects to maintain its growth momentum with a strong focus on quality and operational excellence, while continuing to invest across capacity, portfolio, and geographical expansion.
The company is further diversifying its global manufacturing footprint and service capabilities. Samsung Biologics has secured land for Bio Campus III, reinforcing its commitment to building infrastructure to support next-generation modalities and future biopharmaceutical demand. The company is also expanding its global presence through the planned acquisition of a manufacturing facility in Rockville, Maryland, U.S., strengthening regional proximity to clients and enhancing its global manufacturing network.
In addition, the company continues to pursue strategic collaborations and innovation initiatives. Recently, the company announced collaboration with the Coalition for Epidemic Preparedness Innovations (CEPI) to support outbreak-ready vaccine manufacturing, as well as partnership with Eli Lilly and Company to establish a new Lilly Gateway Labs site aimed at fostering the growth of emerging biotechnology companies.
Detailed information on the Annual General Meeting is available here.
Share article
Related Content